Experience with gemtuzumab ozogamycin ("mylotarg"), and all-trans retinoic acid in untreated acute promyelocytic leukemia

被引:130
作者
Estey, EH [1 ]
Giles, FJ [1 ]
Beran, M [1 ]
O'Brien, S [1 ]
Pierce, SA [1 ]
Faderl, SH [1 ]
Cortes, JE [1 ]
Kantarjian, HM [1 ]
机构
[1] Univ Texas, MD Anderson Canc Ctr, Dept Leukemia, Houston, TX 77030 USA
关键词
D O I
10.1182/blood-2001-12-0174
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
We administered gemtuzumab ozogamycin ("mylotarg"; 9 mg/m(2) day 1 or 5) and all-trans retinoic acid (ATRA) to 19 patients with untreated acute promyelocytic leukemia (APL). There were 3 patients who also received idarubicin because of a white blood cell (WBC) count of more than 30 000/muL. In complete remission (CR), patients were to receive 8 courses of mylotarg (9 mg/m(2) every 4 to 5 weeks) and ATRA; idarubicin was added only for persistent or recurrent polymerase chain reaction (PCR) positivity. The CR rate was 16/19 (84%). All 12 patients tested to date were PCR-negative 2 to 4 months from CR date; none of the 7 patients evaluated subsequently have reverted to PCR positivity (median follow-up in CR was 5 months, up to 14 months). Mylotarg was well tolerated. A median of 5 post-CR courses have been given to date with 3 patients having currently received 8 post-CR courses, and 4 patients receiving 7 post-CR courses, Mylotarg appears active in APL, and repeated administration is feasible. (C) 2002 by The American Society of Hematology.
引用
收藏
页码:4222 / 4224
页数:3
相关论文
共 8 条
[1]  
Appelbaum F R, 1999, Semin Hematol, V36, P2
[2]   Treatment of newly diagnosed acute promyelocytic leukemia without cytarabine [J].
Estey, E ;
Thall, PF ;
Pierce, S ;
Kantarjian, H ;
Keating, M .
JOURNAL OF CLINICAL ONCOLOGY, 1997, 15 (02) :483-490
[3]   Molecular remissions induced by liposomal-encapsulated all-trans retinoic acid in newly diagnosed acute promyelocytic leukemia [J].
Estey, EH ;
Giles, FJ ;
Kantarjian, H ;
O'Brien, S ;
Cortes, J ;
Freireich, EJ ;
Lopez-Berestein, G ;
Keating, M .
BLOOD, 1999, 94 (07) :2230-2235
[4]  
FENAUX P, 1992, LEUKEMIA, V6, P64
[5]  
Jurcic JG, 2000, CLIN CANCER RES, V6, P372
[6]   Prognostic significance of minimal residual disease detection and PML/RAR-α isoform type:: long-term follow-up in acute promyelocytic leukemia [J].
Jurcic, JG ;
Nimer, SD ;
Scheinberg, DA ;
DeBlasio, T ;
Warrell, RP ;
Miller, WH .
BLOOD, 2001, 98 (09) :2651-2656
[7]  
Mandelli F, 1997, BLOOD, V90, P1014
[8]  
Sanz MA, 2000, BLOOD, V96, P1247